{"id":51872,"date":"2024-01-01T00:00:00","date_gmt":"2024-01-01T00:00:00","guid":{"rendered":"https:\/\/ibima.eu\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/"},"modified":"2025-04-10T10:16:39","modified_gmt":"2025-04-10T10:16:39","slug":"five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/","title":{"rendered":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial &#8211; EUROPEAN JOURNAL OF CANCER"},"content":{"rendered":"<p>Reck, M; Ciuleanu, TE; Schenker, M; Bordenave, S; Cobo, M; Juan-Vidal, O; Reinmuth, N; Richardet, E; Felip, E; Menezes, J; Cheng, Y; Mizutani, H; Zurawski, B; Alexandru, A; Carbone, DP; Lu, S; John, T; Aoyama, T; Grootendorst, DJ; Hu, N; Eccles, LJ; Paz-Ares, LG &#8211; 2024 &#8211; 10.1016\/j.ejca.2024.114296<\/p>","protected":false},"excerpt":{"rendered":"<p>Reck, M; Ciuleanu, TE; Schenker, M; Bordenave, S; Cobo, M; Juan-Vidal, O; Reinmuth, N; Richardet, E; Felip, E; Menezes, J; Cheng, Y; Mizutani, H; Zurawski, B; Alexandru, A; Carbone, DP; Lu, S; John, T; Aoyama, T; Grootendorst, DJ; Hu, N; Eccles, LJ; Paz-Ares, LG &#8211; 2024 &#8211; 10.1016\/j.ejca.2024.114296<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2679],"tags":[],"class_list":["post-51872","post","type-post","status-publish","format-standard","hentry","category-publicaciones-b-22"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial - EUROPEAN JOURNAL OF CANCER - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial - EUROPEAN JOURNAL OF CANCER - Ibima\" \/>\n<meta property=\"og:description\" content=\"Reck, M; Ciuleanu, TE; Schenker, M; Bordenave, S; Cobo, M; Juan-Vidal, O; Reinmuth, N; Richardet, E; Felip, E; Menezes, J; Cheng, Y; Mizutani, H; Zurawski, B; Alexandru, A; Carbone, DP; Lu, S; John, T; Aoyama, T; Grootendorst, DJ; Hu, N; Eccles, LJ; Paz-Ares, LG &#8211; 2024 &#8211; 10.1016\/j.ejca.2024.114296\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-01T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-10T10:16:39+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial &#8211; EUROPEAN JOURNAL OF CANCER\",\"datePublished\":\"2024-01-01T00:00:00+00:00\",\"dateModified\":\"2025-04-10T10:16:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\\\/\"},\"wordCount\":83,\"commentCount\":0,\"articleSection\":[\"Publicaciones - B-22\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\\\/\",\"name\":\"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial - EUROPEAN JOURNAL OF CANCER - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2024-01-01T00:00:00+00:00\",\"dateModified\":\"2025-04-10T10:16:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial &#8211; EUROPEAN JOURNAL OF CANCER\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/en\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial - EUROPEAN JOURNAL OF CANCER - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/","og_locale":"en_GB","og_type":"article","og_title":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial - EUROPEAN JOURNAL OF CANCER - Ibima","og_description":"Reck, M; Ciuleanu, TE; Schenker, M; Bordenave, S; Cobo, M; Juan-Vidal, O; Reinmuth, N; Richardet, E; Felip, E; Menezes, J; Cheng, Y; Mizutani, H; Zurawski, B; Alexandru, A; Carbone, DP; Lu, S; John, T; Aoyama, T; Grootendorst, DJ; Hu, N; Eccles, LJ; Paz-Ares, LG &#8211; 2024 &#8211; 10.1016\/j.ejca.2024.114296","og_url":"https:\/\/ibima.eu\/en\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/","og_site_name":"Ibima","article_published_time":"2024-01-01T00:00:00+00:00","article_modified_time":"2025-04-10T10:16:39+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial &#8211; EUROPEAN JOURNAL OF CANCER","datePublished":"2024-01-01T00:00:00+00:00","dateModified":"2025-04-10T10:16:39+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/"},"wordCount":83,"commentCount":0,"articleSection":["Publicaciones - B-22"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/","url":"https:\/\/ibima.eu\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/","name":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial - EUROPEAN JOURNAL OF CANCER - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2024-01-01T00:00:00+00:00","dateModified":"2025-04-10T10:16:39+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/five-year-outcomes-with-first-line-nivolumab-plus-ipilimumab-with-2-cycles-of-chemotherapy-versus-4-cycles-of-chemotherapy-alone-in-patients-with-metastatic-non-small-cell-lung-cancer-in-the-randomize\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial &#8211; EUROPEAN JOURNAL OF CANCER"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/en\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/51872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=51872"}],"version-history":[{"count":1,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/51872\/revisions"}],"predecessor-version":[{"id":52855,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/51872\/revisions\/52855"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=51872"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/categories?post=51872"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/tags?post=51872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}